Best and Worst of Neuroscience and Neurology April 2017 – Brain Blogger (blog)

The number of neuroscience publications steadily grows over the years. In 2006, around 27,000 paper on this subject were published, while in 2015 this number went up to almost 37,000. This is a seriously big increase that reflects the importance of brain science and the growing interest in this field of research. The selection of articles presented here covers a wide range of topics, from purely academic subjects to the findings of clinical significance and newly discovered facts that will be of interest to almost everyone.

On the 25 April 1971, David Eagleman was celebrating his birthday. David is probably one of the best known neuroscientists these days, thanks to his books and TV series. In the academic world, Dr Eagleman is better known for hit works on the relationship between timing of perception and timing of neural signals.

THE BEST

New type of cells discovered in brain

This new discovery touches again on how little we still know about the brain. A new type of brain cell, mural lymphatic endothelial cells, were reported in the article published this week. The function of these cells, which are lymphatic in their origin, is to clean up the brain from accumulating cellular debris and thus prevent the damage to normal healthy cells of the brain.

Artificial synapse capable of learning

Brain synapses are central for our ability to learn. Stimulation of synapses strengthen the connection between the neurons and thus enhances the learning. A similar approach was used when researchers created an electronic synapse called memristor. Although the physical components of this nano-device have nothing to do with the real synapses in brain, the underlying principle is still the same. The devices of this kind will be important for the developing artificial brain.

Doxycycline for treating Parkinsons disease?

Doxycycline has been used to treat bacterial infection for well over 50 years. New findings indicate that this antibiotic may have a new application: to treat Parkinsons disease. This disease is caused by abnormal accumulation and toxicity of protein alpha-synuclein. In cell culture, the scientists observed that the formation of alpha-synuclein aggregates is reduced by 80% in the presence of doxycycline. Mice models with Parkinsons disease fed on the diet with addition of doxycycline improved their symptoms. Human trials with low doses of doxycycline are now being planned.

Psychedelics and higher state of consciousness

The effects of psychedelics such as LSD on brain function are poorly studied. A paper published this month has reported that psychedelics induce increased signal diversity, as shown by brain imaging methods. Signal diversity is considered to be a measure of the complexity of brain activity. In the subjects exposed to the drugs, this measure was higher then the baseline value in the normal condition. Researchers conclude that, under the influence of psychedelics, the brain experiences a changed state of consciousness. The question remains whether this is a better or more desirable state, and whether the psychedelic drugs can be used for therapeutic applications.

Growing brain tissue in a lab

Modelling the brain is very hard due to the complexity of this organ. While most other tissues and even organs can be grown in a laboratory artificially, the brain has resisted attempts thus far. A new paper published this month reported a successful attempt to do exactly this. Researchers successfully turned stem cells into tiny cultures of brain cells with several cell types typical for the midbrain. This is a very important methodological development that will help to facilitate the study of both the healthy brain and various brain pathologies.

THE WORST

Aspirin does not benefit cognitive functions

Aspirin is one of the oldest drugs still in use. Surprisingly, new beneficial qualities of this simple molecule are still being discovered. With only small and manageable side effects, low-dose aspirin is even recommended as a daily drug for older healthy individuals, for reducing the risk of serious conditions such as cardiovascular problems. There were many reports suggesting that aspirin might also be useful for protection against dementia and cognitive decline. However, the meta-analysis of existing data published this month found no evidence to support this view.

Soda drinking damages brain and accelerates its aging

The fact that sugary drinks are bad for general health is well known. New data based on a long-term study show that they are also damaging for brain functions. People consuming two or more sugary drinks at any time per day have poorer memory, decreased overall volume of the brain, and a smaller hippocampus (a part of the brain associated with memory and learning). On the MRI scans their showed more prominent features of brain aging compared to people who dont consume sugary beverages. Interestingly, switching to diet drinks containing artificial sweeteners doesnt help much: people consuming at least one diet soda a day are three times more likely to develop dementia and stroke.

Marmite: bad choice for brain?

Marmite, a food spread popular in the UK, Australia, and New Zealand, might be not as safe and healthy as usually assumed. A rather curious piece of research published this month demonstrated that daily consumption of Marmite (one teaspoon every day) results in a 30% decrease in the brain response to visual stimuli. The effect is explained by the high content of vitamin B12 in Marmite. This vitamin regulates the level of neurotransmitter GABA that has an inhibitory effect on the excitability of some neurons. The findings show that the food we eat may have substantial effects on our brain functioning.

A link between cancer chemotherapy and depression

It was always difficult to figure out if the depression that cancer patients often experience is caused by the psychological stress of having cancer, or also because of chemotherapy. New research data obtained on healthy mice receiving drugs for brain cancer demonstrated that chemotherapy prevents formation of new cells in the hippocampus, a region of brain involved in memory formation and emotions. The treatment also resulted in the release of stress hormones and clear signs of depression. Brain cancer patients appear to be some of the most affected by the treatment-related depression, which remains mostly undiagnosed. Understanding that depression might be related to treatment will help to develop therapies to counteract this effect.

Multitasking: few advantages, brain overloading

The ability to multitask is often praised as a valuable skill, but does it really bring any advantages? New research data seriously questions the value of multitasking. Performing several tasks at the same task reduces productivity by 40%. Moreover, the findings show that frequent switching between tasks interferes with brain activity. Scientists also point out the danger of the continuous use of social media as it is an additional task for our brain and thus reduces the effectiveness of other tasks performed at the same time. It appears that focusing on a single task for a longer period of time brings better results than multitasking.

References:

Andy Wai Kan Yeung, Tazuko K. Goto, W. Keung Leung. The Changing Landscape of Neuroscience Research, 20062015: A Bibliometric Study. Frontiers in Neuroscience, 2017; 11 DOI: 10.3389/fnins.2017.00120

Neil I Bower, Katarzyna Koltowska, Cathy Pichol-Thievend, Isaac Virshup, Scott Paterson, Anne K Lagendijk, Weili Wang, Benjamin W Lindsey, Stephen J Bent, Sungmin Baek, Maria Rondon-Galeano, Daniel G Hurley, Naoki Mochizuki, Cas Simons, Mathias Francois, Christine A Wells, Jan Kaslin, Benjamin M Hogan. Mural lymphatic endothelial cells regulate meningeal angiogenesis in the zebrafish. Nature Neuroscience, 2017; DOI: 10.1038/nn.4558

Sren Boyn, Julie Grollier, Gwendal Lecerf, Bin Xu, Nicolas Locatelli, Stphane Fusil, Stphanie Girod, Ccile Carrtro, Karin Garcia, Stphane Xavier, Jean Tomas, Laurent Bellaiche, Manuel Bibes, Agns Barthlmy, Sylvain Saghi, Vincent Garcia. Learning through ferroelectric domain dynamics in solid-state synapses. Nature Communications, 2017; 8: 14736 DOI: 10.1038/NCOMMS14736

Florencia Gonzlez-Lizrraga, Sergio B. Socas, Csar L. vila, Clarisa M. Torres-Bugeau, Leandro R. S. Barbosa, Andres Binolfi, Julia E. Seplveda-Daz, Elaine Del-Bel, Claudio O. Fernandez, Dulce Papy-Garcia, Rosangela Itri, Rita Raisman-Vozari, Rosana N. Chehn. Repurposing doxycycline for synucleinopathies: remodelling of ?-synuclein oligomers towards non-toxic parallel beta-sheet structured species. Scientific Reports, 2017; 7: 41755 DOI: 10.1038/srep41755

Michael M. Schartner, Robin L. Carhart-Harris, Adam B. Barrett, Anil K. Seth, Suresh D. Muthukumaraswamy. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Scientific Reports, 2017; 7: 46421 DOI: 10.1038/srep46421

Anna S. Monzel, Lisa M. Smits, Kathrin Hemmer, Siham Hachi, Edinson Lucumi Moreno, Thea van Wuellen, Javier Jarazo, Jonas Walter, Inga Brggemann, Ibrahim Boussaad, Emanuel Berger, Ronan M.T. Fleming, Silvia Bolognin, Jens C. Schwamborn. Derivation of Human Midbrain-Specific Organoids from Neuroepithelial Stem Cells. Stem Cell Reports, 2017; DOI: 10.1016/j.stemcr.2017.03.010

Stubbs, Stefania Maggi, Trevor Thompson, Patricia Schofield, Christoph Muller, Ping-Tao Tseng, Pao-Yen Lin, Andr F. Carvalho, Marco Solmi. Low-Dose Aspirin Use and Cognitive Function in Older Age: A Systematic Review and Meta-analysis. Journal of the American Geriatrics Society, 2017; DOI: 10.1111/jgs.14883

Matthew P. Pase et al. Sugar- and Artificially Sweetened Beverages and the Risks of Incident Stroke and Dementia: A Prospective Cohort Study. Stroke, April 2017 DOI: 10.1161/STROKEAHA.116.016027

Matthew P. Pase, Jayandra J. Himali, Paul F. Jacques, Charles DeCarli, Claudia L. Satizabal, Hugo Aparicio, Ramachandran S. Vasan, Alexa S. Beiser, Sudha Seshadri. Sugary beverage intake and preclinical Alzheimers disease in the community. Alzheimers & Dementia, 2017; DOI: 10.1016/j.jalz.2017.01.024

Anika K Smith, Alex R Wade, Kirsty EH Penkman, Daniel H Baker. Dietary modulation of cortical excitation and inhibition. Journal of Psychopharmacology, 2017; 026988111769961 DOI: 10.1177/0269881117699613

M Egeland, C Guinaudie, A Du Preez, K Musaelyan, P A Zunszain, C Fernandes, C M Pariante, S Thuret. Depletion of adult neurogenesis using the chemotherapy drug temozolomide in mice induces behavioural and biological changes relevant to depression. Translational Psychiatry, 2017; 7 (4): e1101 DOI: 10.1038/tp.2017.68

Juha M. Lahnakoski, Iiro P. Jskelinen, Mikko Sams, Lauri Nummenmaa. Neural mechanisms for integrating consecutive and interleaved natural events. Human Brain Mapping, 2017; DOI: 10.1002/hbm.23591

Image via felixioncool/Pixabay.

Read the original post:
Best and Worst of Neuroscience and Neurology April 2017 - Brain Blogger (blog)

Global Immunology Partnering 2010 – 2017: Deal trends, players and financials – PR Newswire (press release)

LONDON, May 17, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/4882472/

Description Global Immunology Partnering 2010 to 2017 provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Immunology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Immunology partnering agreement structure Immunology partnering contract documents Top Immunology deals by value Most active Immunology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.

The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Immunology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Immunology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Immunology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Immunology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2010. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.

Report scope Global Immunology Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.

Global Immunology Partnering 2010 to 2017 includes: - Trends in Immunology dealmaking in the biopharma industry since 2010 - Analysis of Immunology deal structure - Access to headline, upfront, milestone and royalty data - Access to hundreds of Immunology deal contract documents - Comprehensive access to over 3500 Immunology deal records - The leading Immunology deals by value since 2010 - Most active Immunology dealmakers since 2010

The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.

In Global Immunology Partnering 2010 to 2017, available deals and contracts are listed by: - Headline value - Upfront payment value - Royalty rate value - Stage of development at signing - Deal component type - Technology type - Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Immunology Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 700 immunology deals.

Analyzing actual contract agreements allows assessment of the following: - What are the precise rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How are the sales and payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law?

Benefits Global Immunology Partnering 2010 to 2017 provides the reader with the following key benefits: - In-depth understanding of Immunology deal trends since 2010 - Access Immunology deal headline, upfront, milestone and royalty data - Research hundreds of actual contracts between Immunology partner companies - Comprehensive access to over 750 links to actual Immunology deals entered into by the world's biopharma companies - Indepth review of Immunology deals entered into by the top 25 most active dealmakers - Benchmark the key deal terms companies have agreed in previous deals - Identify key terms under which companies partner Immunology opportunities Download the full report: https://www.reportbuyer.com/product/4882472/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-immunology-partnering-2010---2017-deal-trends-players-and-financials-300459424.html

SOURCE ReportBuyer

http://www.reportbuyer.com

Excerpt from:
Global Immunology Partnering 2010 - 2017: Deal trends, players and financials - PR Newswire (press release)

CEL-SCI Scientist Presents at AAI – IMMUNOLOGY 2017 Meeting – Business Wire (press release)

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today announced that Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular Immunology, presented additional data on its LEAPS rheumatoid arthritis (RA) vaccine candidates CEL-4000 and CEL-2000 at IMMUNOLOGY 2017, the annual meeting of the American Association of Immunologists (AAI), May 12 16 in Washington, D.C.

The title of his poster is Key serum cytokine markers for evaluating the efficacy of vaccine therapy in autoimmune models of rheumatoid arthritis. The abstract can be viewed online or found through the conference website at: http://www.immunology2017.org.

Dr. Zimmerman and the research team concluded that serum concentrations and ratios of key disease-related cytokines can predict therapeutic efficacy in different animal models of RA. The data showed that a reduced RA disease progression was observed in mice treated with LEAPS vaccines and was accompanied by decreased pro-inflammatory cytokines level and increased ratios of anti-inflammatory/regulatory to pro-inflammatory cytokines. Thus, a successful vaccine therapy appears to be associated with a ratio shift in favor of anti-inflammatory/regulatory cytokines. The ability to predict cytokine responses to therapy should allow for better design or choice of the appropriate immunomodulatory LEAPS vaccines and other therapies in RA.

About LEAPS

L.E.A.P.S. (Ligand Epitope Antigen Presentation System) is a CEL-SCI patented platform technology designed to stimulate antigen-specific immune responses in T-cells using synthetic peptides. LEAPS constructs physically link the antigenic peptide with a T-cell binding ligand and are delivered directly to the recipient by injection or through absorption onto mucosal surfaces, potentially enhancing T-cell responses to a particular antigen.

About CEL-SCI

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K and 10-K/A for the year ended September 30, 2016. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

See the original post here:
CEL-SCI Scientist Presents at AAI - IMMUNOLOGY 2017 Meeting - Business Wire (press release)

Global Cancer Immunology and Oncolytic Virology Technologies and Markets Report 2017: Market Should – PR Newswire (press release)

The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies.

This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report.

Report Includes

Key Topics Covered:

1: Introduction

- Goals and Objectives - Reasons for Doing This Study - Intended Audience - Scope of The Study - Information Sources for the Technology Assessment - Forecasting Methodology - Geographic Breakdown

2: Summary and Highlights

3: Overview

- Past and Present of Cancer Immunology - What is Cancer? - Treating Cancer - Challenges in Treating Cancer - Cancer and the Immune System - Immunotherapy - Towards Combination Immunotherapy - Focusing on Cell-mediated Adaptive Immunity - Fine Tuning Versus Boosting Cancer Immunity - Early Versus Advanced Stage Cancer Immunotherapy - Personalized Treatment Paradigm - Clinically Significant Types of Cancers - Future of Checkpoint Inhibitors, Cancer Vaccines, and Oncolytic Virology

4: Overview of Cancer Immunotherapy

- Immune System and Immunotherapy - Therapeutic Monoclonal Antibodies - Checkpoint Inhibitors - Biological Response Modifiers - Vaccines - Other - Expanded Information on Selected Product Candidates and Recent Regulatory Applications

5: Oncolytic Virology

6: Major Markets

- Markets for Immunotherapy Products - Markets for Oncolytic Virology Products

7: Company Profiles

- Abbvie Inc. - Adaptimmune - Aduro Biotech - Advantagene - Advaxis Immunotherapies - Amgen - Argos Therapeutics - Ariad Pharmaceuticals - Arog Pharmaceuticals - Aserta Pharmaceuticals - Astellas - Astrazeneca - Avax Technologies - Bavarian Nordic - Bayer Healthcare - Biovex - Boehringer Ingelheim - Boston Biomedical - Bristol-Myers Squibb - Cell Medica - Celldex Therapeutics - Celgene Corp. - Chugai - Cold Genesys - Daiichi Sankyo Co. - Dendreon - Dnatrix - Eisai - Eli Lilly - F Hoffmann La Roche AG - Genelux - Gilead Sciences Inc. - Glaxosmithkline Plc - Hanmi Pharmaceutical - Heat Biologics - Immune Design - Immunocellular Therapeutics Ltd. - Immunomedics Inc. - Immunovaccine Inc. - Immunovative Therapies - Incyte Ciorp. - Inovio Pharmaceuticals Inc. - Janssen Pharmaceuticals - Kadmon Pharmaceuticals Corp. - Kite Pharmaceuticals Inc. - Kyowa Hakko Kirin Co. Ltd. - Ligand Pharmaceuticals Inc. - Lion Biotechnologies - Lokon Pharmaceuticals AB - Medimmune - Merck & Co. - Merck Kgaa - Merck Serono - Medigene AG - Mirati Therapeutics - Multivir Inc. - Newlink Genetics - Northwest Biotherapeutics - Novartis Pharma Services AG - Oncolys Biopharma Inc. - Oncolytics Biotech Inc. - Oncomed Pharmaceuticals Inc. - Oncos Therapeutics Ltd. - Ono Pharmaceutical Co. - Otsuka Pharmaceutical Co., Ltd. - Pfizer Inc. - Plexxikon Inc. - Portola Pharmaceuticals Inc. - Provectus Biopharmacueticals Inc. - Psioxus Therapeutics Ltd. - Sanofi SA - Seattle Genetics - Shanghai Sunway Biotech Co. Ltd. - Shenzhen Sibiono Gentech - Sillajen Biotherapeutics Inc. - Spectrum Pharmaceuticals - Takara Bio Inc. - Takeda Co. Ltd. - Tapimmune Inc. - Targovax - Teva Pharmaceutical Industries Ltd. - TG Therapeutics Inc. - Tracon Pharmaceuticals Inc. - Transgene - VCN Biosciences - Ventirx - Verastem Inc. - Viralytics Ltd. - Virttu Biologics Ltd - Vyriad - Western Oncolytics Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/fpck42/cancer_immunology

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cancer-immunology-and-oncolytic-virology-technologies-and-markets-report-2017-market-should-reach-965-billion-by-2021-from-730-billion-in-2016-at-a-cagr-of-57---research-and-markets-300458203.html

SOURCE Research and Markets

http://www.researchandmarkets.com

More:
Global Cancer Immunology and Oncolytic Virology Technologies and Markets Report 2017: Market Should - PR Newswire (press release)

OpenAI takes the robotic imitation of human behavior into a whole new level – The TechNews

OpenAI takes the robotic imitation of human behavior into a whole new level

OpenAI, anElon Musk-backed nonprofit artificial intelligence platform just announced a new milestone in training robots. They are working with a new algorithm known as one-shot imitation learning, which lets human being train a robot by demonstrating it first in virtual reality.

In the video below, a person is trying to teach a robotic arm how to stack a series of colored cube-shaped blocks by first performing it manually within a VR environment. The whole system is powered by two neural networks. The first one determines the objects spatial position to the robot by taking a camera image. However, the neural network was trained only with a host of simulated images, which means it knew how to cooperate with the real world before it ever actually met it. The second one emulates any task the demonstrator shows it by scanning through recorded actions and observing frames telling it what to do next.

Our robot has now learned to perform the task even though its movements have to be different than the ones in the demonstration, explains Josh Tobin, a member of OpenAIs technical staff. With a single demonstration of a task, we can replicate it in a number of different initial conditions. Teaching the robot how to build a different block arrangement requires only a single additional demonstration.

The model is currently a prototype, but this concept could help researchers in the long run. They could use this concept to teach the robots more complex tasks in future without using any physical elements at all. OpenAIs long term plan is to give the AI the ability to learn to adapt to unpredictable changes in the environment.

Read more:
OpenAI takes the robotic imitation of human behavior into a whole new level - The TechNews

Pushy AI Bots Nudge Humans to Change Behavior – Scientific … – Scientific American

When people work together on a project, they often come to think theyve figured out the problems in their own respective spheres. If trouble persists, its somebody elseengineering, say, or the marketing departmentwho is screwing up. That local focus means finding the best way forward for the overall project is often a struggle. But what if adding artificial intelligence to the conversation, in the form of a computer program called a bot, could actually make people in groups more productive?

This is the tantalizing implication of a study published Wednesday in Nature. Hirokazu Shirado and Nicholas Christakis, researchers at Yale Universitys Institute for Network Science, were wondering what would happen if they looked at artificial intelligence (AI) not in the usual wayas a potential replacement for peoplebut instead as a useful companion and helper, particularly for altering human social behavior in groups.

First the researchers asked paid volunteers arranged in online networks, each occupying one of 20 connected positions, or nodes, to solve a simple problem: Choose one of three colors (green, orange or purple) with the individual, or local, goal of having a different color from immediate neighbors, and the collective goal of ensuring that every node in the network was a different color from all of its neighbors. Subjects pay improved if they solved the problem quickly. Two thirds of the groups reached a solution in the allotted five minutes and the average time to a solution was just under four minutes. But a third of the groups were still stymied at the deadline.

The researchers then put a botbasically a computer program that can execute simple commandsin three of the 20 nodes in each network. When the bots were programmed to act like humans and focused logically on resolving conflicts with their immediate neighbors, they didnt make much difference. But when the researchers gave the bots just enough AI to behave in a slightly noisy fashion, randomly choosing a color regardless of neighboring choices, the groups they were in solved the problem 85 percent of the timeand in 1.7 minutes on average, 55.6 percent faster than humans alone.

Being just noisy enoughmaking random color choices about 10 percent of the timemade all the difference, the study suggests. When a bot got much noisier than that, the benefit soon vanished. A bots influence also varied depending on whether it was positioned at the center of a network with lots of neighbors or on the periphery.

So why would making what looks like the wrong choicein other words, a mistakeimprove a groups performance? The immediate result, predictably, was short-term conflict, with the bots neighbors in effect muttering, Why are you suddenly disagreeing with me? But that conflict served to nudge neighboring humans to change their behavior in ways that appear to have further facilitated a global solution, the co-authors wrote. The humans began to play the game differently.

Errors, it seems, do not entirely deserve their bad reputation. There are many, many natural processes where noise is paradoxically beneficial, Christakis says. The best example is mutation. If you had a species in which every individual was perfectly adapted to its environment, then when the environment changed, it would die. Instead, random mutations can help a species sidestep extinction.

Were beginning to find that errorand noisy individuals that we would previously assume add nothingactually improve collective decision-making, says Iain Couzin, who studies group behavior in humans and other species at the Max Planck Institute for Ornithology and was not involved in the new work. He praises the deliberately simplified model used in the Nature study for enabling the co-authors to study group decision-making in great detail, because they have control over the connectivity. The resulting ability to minutely track how humans and algorithms collectively make decisions, Couzin says, is really going to be the future of quantitative social science.

But how realistic is it to think human groups will want to collaborate with algorithms or botsespecially slightly noisy onesin making decisions? Shirado and Christakis informed some of their test groups that they would be partnering with bots. Perhaps surprisingly, it made no difference. The attitude was, I don't care that youre a bot if youre helping me do my job, Christakis says. Many people are already accustomed to talking with a computer when they call an airline or a bank, he adds, and the machine often does a pretty good job. Such collaborations are almost certain to become more common amid the increasing integration of the internet with physical devices, from automobiles to coffee makers.

Real-world, bot-assisted company meetings might not be too far behind. Business conferences already tout blended digital and in-person events, featuring what one conference planner describes as integrated online and offline catalysts that use virtual reality, augmented reality and artificial intelligence. Shirado and Christakis suggest slightly noisy bots are also likely to turn up in crowdsourcing applicationsfor instance, to speed up citizen science assessment of archaeological or astronomical images. They say such bots could also be useful in social mediato discourage racist remarks, for example.

But last year when Microsoft introduced a twitter bot with simple AI, other users quickly turned it into epithetspouting bigot. And the opposite concern is that mixing humans and machines to improve group decision-making could enable businessesor botsto manipulate people. Ive thought a lot about this, Christakis says. You can invent a gun to hunt for food or to kill people. You can develop nuclear energy to generate electric power or make the atomic bomb. All scientific advances have this Janus-like potential for evil or good.

The important thing is to understand the behavior involved, so we can use it to good ends and also be aware of the potential for manipulation, Couzin says. Hopefully this new research will encourage other researchers to pick up on this idea and apply it to their own scenarios. I dont think it can be just thrown out there and used willy-nilly.

Go here to see the original:
Pushy AI Bots Nudge Humans to Change Behavior - Scientific ... - Scientific American

How Understanding Human Behavior Can Open Up New Design Opportunities – Core77.com

There are few people in the design world more familiar with field research, and the extensive travel that goes with it, than Jan Chipchase. On May 6th, Jan launched what has turned out to be a very successful Kickstarter campaign to publish his most recent book,The Field Study Handbook. There's still time to pre-order a copy of what looks to be a fascinating read, even if field research in the Hindu Kush is not on your immediate list of things to do.

Jan is a researcher, writer and photographer whose work focuses on the intersection of design, tech, human behavior and culture. Over the years, he's led research teams investigating both mainstream and emerging markets for Nokia and frog design. In 2014, he founded Studio D, a research, design and innovation consultancy, and later used his extensive travel experiences to create an ultra-light luggage brand, SDR Traveller.

I had a chance to catch up with Jan to talk about the book launch and other recent adventures and activities, as well as ask for some travel advice.

This interview has been edited for length and clarity.

Core77: In addition to Studio D and SDR Traveller, I see also that you run as service called The Fixer List. What is that all about? It seems mysterious.

JC: Fixers are a staple of field research, at least with the way I run projects. Each project includes a local crew that is usually led by someone I call a "fixer". They come from very diverse backgrounds, often speak multiple languages, have a very good sense of their home locale and know how to hustle. Over the years, many of these connections have stayed in touch.

The Fixer List is the Studio D list of unusual talent that we can draw on to run projects around the world. We receive a lot of applicants.

You spend a large percentage of your time on the road, traveling extensively across the world. What are some notable recent field trips you've taken?

JC: Saudi Arabia was interesting and challenging. We were there gathering insights to understand the value proposition of a new brand offering. The new service, Jawwy, went live last year. The team had to achieve a high level of understanding of the local culture and how it maps to a mobile service, in only a month. Many foreigners would struggle to achieve this level of understanding in a lifetime. All credit to our local team of ten people for getting us that far.

Last year I took a tough, 7,000km overland expedition through Kyrgyzstan, Tajikistan's GBAO region and China's western provinces. The trip was full of remote communities, dubious border crossings, permeable borders and lots of checkpoints. I learned a lot on that trip and wrote up my thoughts in a Medium post called 61 Glimpses of the Future.

Another interesting trip involved training a client's team on field research methods, including setting up a mountain retreat at the edge of the Tibetan Plateau to process the data. On every project we get to ask "Where is the best place to figure out x?" and "Where do we want to be today?"

Naturally, the Kickstarter includes expeditions as rewards, if you're up for A Short Walk in the Hindu Kush.

In the Kickstarter video, you mention that the book is part of a mission to reframe the relationship between those that make things and those that consume them. Can you talk about this a bit?

JC: Increasingly, the impetus for creating new products will be based on the data analytics of mass consumption, feedback on marketing strategies, and optimized value engineering. The product creators are removed from their audience by several steps, and it is easy to lose touch with that actual audience. The ability to gather an over abundance of data only compounds the problem. As more data comes on stream, revealing what people are doing and how, there is a growing danger of people being treated as little more than lines in a database, stripped of personality and context, there solely to be mined and monetized.

Field research is defined by closeness and empathy. You get close to those you are studying, and in doing so, develop a deeper empathy for their lives and ways of living. You then take that empathy andin the best casesreflect it back on them through your work. In the right hands, it generates very rich, and very nuanced, data that is capable of answering why people do what they do. Understanding the motivations behind people's actions can lead to very different outcomes, if all you knew before was what people did and how.

I try (and usually fail) to not pack too much when I travel. As a seasoned traveller what are some of your suggestions and tips for packing?

JC: Everybody over packs. It's human nature! By packing less, you're actually more flexible and better able to alter your planned itinerary to react to interesting opportunities. My own preference is to use hand-held luggage (no wheels allowed!), make sure the bag can fit under an economy-class seat or a business class foot-well, and even with that small size, still leave room in your bag for things you might pick up along the way. I wrote about how the psychology of packing impacts the experience of the journey, and it still holds true.

Check out the book, and other rewards available for pre-order on the Kickstarter page forThe Field Study Handbook.

Article illustration, and book illustrations, by Lee Phillips (@leejohnphillips)

Join over 300,000 designers who stay up-to-date with the Core77 newsletter...

Subscribe

Test it out; it only takes a single click to unsubscribe

Stuart Constantine is a co-founder of Core77. He lives in Connecticut with his wife, three children, a collection of bikes and guitars.

Read more here:
How Understanding Human Behavior Can Open Up New Design Opportunities - Core77.com

How Robots Acting Randomly Can Help Speed Human Problem-Solving – Live Science

Robots that occasionally act randomly can help groups of humans solve collective-action problems faster, new research has shown.

Playing a game with someone unpredictable can be annoying, particularly when you're on the same team. But in an online game designed to test group decision-making, adding computer-controlled players that sometimes behave randomly more than halved the time it took to solve the problem, according to the new study.

That shouldn't come as too much of a surprise, said study leader Nicholas Christakis, director of the Human Nature Lab at Yale University. Random mutations make evolution possible; random movements by animals in flocks and schools enhances group survival; and computer scientists often introduce noise a statistical term for random or meaningless information to improve search algorithms, he said. [Super-Intelligent Machines: 7 Robotic Futures]

But the discovery that these effects are mirrored in combined groups of humans and machines could have wide-ranging implications, Christakis told Live Science. To start, self-driving cars will soon share roads with human drivers, and more people may soon find themselves working alongside robots or with "smart" software.

In the study, published online today (May 17) in the journal Nature, the researchers describe how they recruited 4,000 human workers from Amazon's Mechanical Turk online crowdsourcing platform to play an online game.

Each participant was assigned at random to one of 20 locations, or "nodes," in an interconnected network. Players can select from three colors and the goal is for every node to have a different color from the neighbors they are connected to.

Players can see only their neighbors' colors, which means that while the problem may seem to have been solved from their perspective, the entire game may still be unsolved.

While highly simplified, this game mimics a number of real-world problems, such as climate change or coordinating between different departments of a company, Christakis said, where from a local perspective, a solution has been reached but globally it has not.

In some games, the researchers introduced software bots instead of human players that simply seek to minimize color conflicts with neighbors. Some of these bots were then programmed to be "noisy," with some having a 10 percent chance of making a random color choice and others a 30 percent chance.

The researchers also experimented with putting these bots in different areas of the network. Sometimes they were placed in central locations that have more connections to other players, and other times they were just placed at random or on the periphery where there are fewer links.

What the researchers found was that games in which bots exhibiting 10 percent noise were placed in the center of the network were typically solved 55.6 percent times faster than sessions involving just humans.

"[The bots] got the humans to change how they interacted with other humans," Christakis said. "They created these kinds of positive ripple effects to more distant parts of the network. So the bots in a way served a kind of teaching function." [The 6 Strangest Robots Ever Created]

There's a fine balance, though. The researchers found that the bots that had a 30 percent change of making a random color choice introduced too much noise and increased the number of conflicts in the group-decision-making process. Similarly, bots that exhibited no randomness actually reduced the randomness of human players, resulting in more of them becoming stuck in unresolvable conflicts, the scientists said.

Iain Couzin, director of the Max Planck Institute for Ornithology in Germany and an expert in collective behavior, said the study's findings mimic what he has seen in animals, where uninformed individuals can actually improve collective decision-making.

He said it is a very important first step toward a scientific understanding of how similar processes impact human behavior, particularly in the context of interactions between humans and machines.

"Already we are making our decisions in the context of algorithms and that's only going to expand as technology advances," he told Live Science. "We have to be prepared for that and understand these types of processes. And we almost have a moral obligation to improve our collective decision-making in terms of climate change and other decisions we need to make at a collective level for humanity."

The new research also points to an alternative paradigm for the widespread introduction of artificial intelligence into society, Christakis said. "Dumb AI" (bots that follow simple rules compared to sophisticated AI) could act as a catalyst rather than a replacement for humans in various kinds of cooperative networks, ranging from the so-called sharing economy (which encompasses services like ride-sharing, home-lending and coworking) to citizen science.

"We're not trying to build AlphaGo or [IBM's] Watson to replace a person we are trying to build technology that helps supplement groups of people, and in a way, I think that might be a little less frightening," Christakis said. "The bots don't need to be very smart because they're interacting with smart humans. They don't need to be able to do stuff by themselves; they just need to help the humans help themselves," he added.

Original article on Live Science.

See the rest here:
How Robots Acting Randomly Can Help Speed Human Problem-Solving - Live Science

Turns Out Nazis Have Some Pretty Wrong Views About Genetics – New York Magazine

Photo: Stefano Bianchetti/Getty Images

Most people tend to have a certain idea about their heritage: that they simply are, well, whatever they are. Scottish or German or Nigerian or whatever else. Maybe theres some other stuff mixed in there, sure, but most people have a sense that theyre from one particular place, and thats where their culture and maybe some of their values originates.

Naturally, DNA tells a more complicated story, and a new article in Science by Ann Gibbons very usefully punctures a bunch of myths, some of them pretty harmful, about human ancestry. The vast majority of us are mutts, it turns out, and oftentimes the genetic heritage we think we have bears little resemblance to whats actually hiding in our chromosomes.

Gibbons starts the article by quoting a German neo-Nazi, doing what neo-Nazis tend to do, expressing alarm about the arrival of Syrian refugees and the prospect of them sullying his precious German genetic heritage.

From there she swiftly moves to the main point of the article:

Using revolutionary new methods to analyze DNA and the isotopes found in bones and teeth, scientists are exposing the tangled roots of peoples around the world, as varied as Germans, ancient Philistines, and Kashmiris. Few of us are actually the direct descendants of the ancient skeletons found in our backyards or historic homelands. Only a handful of groups today, such as Australian Aborigines, have deep bloodlines untainted by mixing with immigrants.

That aforementioned notion of German purity, to take one example, comes from a Nazi mangling of an already somewhat thinly sourced story about a Germanic fighter named Arminius who supposedly led a rebellion against the Romans 2,000 years ago the Nazis portrayed him as a blond-haired member of a supposed master race.

Now, it shouldnt be surprising that Nazis dont have a particularly sophisticated grip on genetics. But this article is still an interesting, comprehensive look at where researchers are in their quest to understand humanitys genetic legacy. And the short, also-unsurprising answer is: Weve moved around a lot and mixed it up a lot.

Gibbonss piece also usefully complicates the notion of genetic superiority, highlighting just how historically contingent this idea is. For example, she writes of two different groups that collided at one point and produced offspring: The unions between the Yamnaya and the descendants of Anatolian farmers catalyzed the creation of the famous Corded Ware culture, known for its distinctive pottery impressed with cordlike patterns According to DNA analysis, those people may have inherited Yamnaya genes that made them taller; they may also have had a then-rare mutation that enabled them to digest lactose in milk, which quickly spread It was a winning combination. The Corded Ware people had many offspring who spread rapidly across Europe. Today, of course, very few people are aware of the Corded Ware culture a group that was very much, for random genetic reasons, in the right place at the right time.

For most of human history, humans havent been great at recording history accurately, so along the way many cultures have developed myths about their lineage, about who was where, when. A lot of the time, the straightforward stories people tell to be proud of themselves and their ancestors are oversimplifications, at best. In the worst cases, these myths lead to ideologies like nationalism.

Its important to understand the appeal and functional role of bloodline myths, of course: This group could sully our bloodlines packs a bit more of a visceral punch than I am nervous this new group will cause the neighborhood to change. Because people dont tend to really understand genetics, and because the subject efficiently taps into many peoples most intimate feelings about disgust and purity, such talk can be a useful way to rile people up, almost always for the worse. Which is why its important to understand just how superficial it really is.

The psychology of how we choose who to leave out.

Research suggests that sexism in hiring cant explain the entire gender gap in leadership positions theres other stuff going on, too.

Just about everyone, everywhere, is a complicated mutt, and stories about pure bloodlines are almost always false.

Labels like organic and natural are impossibly vague and often misleading.

Most adults can do a decent job of understanding other peoples internal mental states. Not the leader of the free world.

Or its about to be, at least. Thats just the life cycle of any fad.

It might seem counterintuitive to advertise a place for injection-drug users to shoot up, but theres smart public-health reasoning behind the idea.

Not exactly, but theres some merit to the myth.

Time to find another hangover remedy.

A realization about monogamy that should make anyone getting married feel a little more hopeful.

Its a mixed bag.

The science behind a common-sense piece of advice.

Giving your mind time to wander is a key part of creativity.

Theres a bit of dissent within the American Psychological Association about the role of video games in contributing to violence.

A new TEDx video sums up the research of Bella DePaulo, a social psychologist who has been chipping away at the many myths surrounding marriage.

No matter how long they live in a loud urban environment.

The WHO and the CDC offer different recommendations for proper handwashing technique. Which is right?

Drinking with the author of Cork Dork, a new book about the obsessive world of wine.

A new study explains.

During the current fixation on the intersection of design and psychology, its worth remembering what workers are going through at the moment.

Here is the original post:
Turns Out Nazis Have Some Pretty Wrong Views About Genetics - New York Magazine

International genetics symposium launches in Hong Kong – Baylor College of Medicine News (press release)

The worlds top geneticists will come together for the first-ever Joint Symposium in Clinical Genetics May 19 - 21, 2017. The symposium, which will become an annual event, will be hosted at the Postgraduate Education Centre in the School of Public Health at the Prince of Wales Hospital in Hong Kong.

Organized in partnership by the Department of Molecular and Human Genetics at Baylor College of Medicine and the Department of Obstetrics and Gynecology and the Department of Pediatrics at the Chinese University of Hong Kong, the goals of the symposium are to educate and update clinicians and scientists on the application of clinical genetics to genomic medicine and to highlight cutting-edge technologies and scientific discoveries in clinical genetics and genomics. Through the event, the partner organizations hope to lead in the implementation of genetic medicine in Asia.

The symposium will connect experts and leaders in the field from Baylor with those in Hong Kong and across Asia. In addition to the symposium programming, attendees and organizers will celebrate the establishment of the joint CUHK-BCM Center of Medical Genetics, which aims to promote high-quality training and conduct state-of-the-art research in medical genetics.

We are thrilled to see this symposium come to life, said Dr. Brendan Lee, chair of molecular and human genetics at Baylor. Ever since joining forces with the Chinese University Hong Kong, we have wanted to host a conference that would bring all of these talented minds together to discuss the latest developments and research in the field of molecular and human genetics. There is the potential for incredible work to come out of this three-day symposium.

The symposium will play host to key speakers in the field, including Baylors Dr. Igna Van Den Veyver, Dr. Richard Gibbs, Dr. Art Beaudet, Dr. James Lupski and Lee, who also is the Robert and Janice McNair Endowed Chair and Professor of Molecular and Human Genetics, and Dr. Dennis Lo, Dr. Rossa Chiu, Dr. Tak Yeung Leung and Dr, Richard Choy, all with the Chinese University of Hong Kong.

Oral presentations will address relevant topics, including non-invasive prenatal genetic diagnosis, genomic technologies and the future, genetics and neurological diseases, inborn errors of metabolism, genetics and congenital cardiac diseases, genetic screening and counseling of diseases, and genetics and skeletal dysplasia, among others.

For more information about programming, visit the symposiums website.

Read more from the original source:
International genetics symposium launches in Hong Kong - Baylor College of Medicine News (press release)